JD Health stock forecast
MyStockButler's October 2026 analysis: JD Health's weighted scenario is HKD36.80 in October 2027, equivalent to a 5% loss including dividends. It hinges on durable earnings growth, cash conversion and order economics.
Where could JD Health's shares be by October 2029?
The forecast sees limited near-term upside, followed by a stronger three-year outcome. The probability-weighted price is HKD36.80 in October 2027, equivalent to a 5% loss including dividends. It rises to HKD41.89 in October 2028, an 8% gain, and HKD47.84 in October 2029, a 23% gain. The October 2029 outcomes range from HKD20.45 in the bear case to HKD87.46 in the bull case, against today’s HKD38.92.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 23.14 (-41 %) | 21.74 (-44 %) | 20.45 (-47 %) |
| Base | 60 % | 38.84 (-0 %) | 43.81 (+13 %) | 49.36 (+27 %) |
| Bull | 15 % | 51.43 (+32 %) | 67.83 (+74 %) | 87.46 (+125 %) |
| Weighted | 100 % | 36.80 (-5 %) | 41.89 (+8 %) | 47.84 (+23 %) |
What has to go right, and what could go wrong for JD Health?
The bear path reaches only CNY5,720m in the first period and CNY5,922m in the second. It assumes slower revenue growth, price competition and higher fulfillment or expansion costs. The bull path starts at CNY7,708m and reaches CNY9,570m in the second period, requiring specialty-drug refills, paid care, denser delivery and measurable productivity gains. JD Health introduced 65 new drugs in H1 2026, but it has not shown channel profit per order or AI savings.
| October 2027 | October 2028 | October 2029 | |
|---|---|---|---|
| Earnings | 7,007 (5,720 / 7,708) | 7,878 (5,922 / 9,570) | 8,848 (6,200 / 11,648) |
| Shares (millions) | 3,180 (3,196 / 3,170) | 3,170 (3,202 / 3,150) | 3,160 (3,208 / 3,130) |
| Dividends per share | 0.00 (0.00 / 0.00) | 0.00 (0.00 / 0.00) | 0.00 (0.00 / 0.00) |
| Price to earnings | 15.00 (11.00 / 18.00) | 15.00 (10.00 / 19.00) | 15.00 (9.00 / 20.00) |
How much cash does JD Health really make?
After capital spending, lease payments and interest, free cash flow was RMB9,943.789 million in 2025. Subtracting stock compensation gives “real free cash flow” of RMB9,353.065 million. Subtracting the working-capital release as a further sensitivity gives RMB5,751.663 million. This is an analytical view, not a reported subtotal, but it better separates operating cash from timing.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 10,173.949 | 4,332.367 | 4,604.778 | 5,905.149 | 3,430.72 |
| − Capital spending | 151.009 | 46.355 | 69.333 | 2,270.709 | 518.163 |
| = Free cash flow | 9,943.789 | 4,240.404 | 4,492.127 | 3,578.026 | 2,875.311 |
| − Stock pay | 590.724 | 1,129.6 | 1,847.789 | 2,104.278 | 2,579.709 |
| = Real free cash flow | 9,353.065 | 3,110.804 | 2,644.338 | 1,473.748 | 295.602 |
| Real free cash flow, % of revenue | 12.7% | 5.3% | 4.9% | 3.2% | 1.0% |
What does an investor pay for JD Health today?
Its next-12-month P/E is 14.7x. P/E means how many units of share value investors pay for each unit of annual profit. JD Health reports IFRS profit under standard accounting rules and non-IFRS profit after management removes selected items. In H1 2026, those figures were RMB3.44 billion and RMB3.87 billion. The larger adjusted denominator makes the stock look cheaper, so investors must decide whether the excluded costs are genuinely unusual.